• xxx

Programme Schedule

2017 Oncology Forum
DAY 1

THURSDAY 15th JUNE 2017



08:30 UKOMIC & EOCC Joint Committee Meeting (special invitation – members only)
08:30 UKONS ‘Introducing the impact of immunotherapies – adapting the toolkit and developing good practice guidance in the empowerment and proactive monitoring of patients.’ (Special invitation only - strictly UKONs members only)
10:00 NCRi Anorectal Subgroup Committee meeting (special invitation – members only)
10:15 - 12:00 BOPA Committee Meeting (special invitation - strictly BOPA members only)
10:30 - 12:00 The Association of Cancer Physicians (ACP) - Annual General Meeting (special invitation only - strictly ACP Members only)
10:45
EASI-SWITCH Investigator meeting (special invitation only)
12:00 Arrival, registration, buffet lunch, exhibition and
Cancer Charity Corner 8
13:00 Welcome and
Opening Keynote Speaker
Dr Sergio A. Quezada, PH.D
14:00 - 14:25 Coffee & Exhibition
14:30 Clinical Sessions x 9 (see below)
17:30 Question Time
18:45 Meeting concludes
20:00 Conference dinner (meet in exhibition area from 19:30hrs for networking)
DAY 2

FRIDAY 16th JUNE 2017

08:30 Main plenary
08:45 Clinical Sessions X 9 (see below)
10:00 - 11:00 WORKSHOP - De-mystifying the science behind cancer immunotherapy (optional complimentary workshop for our industry colleagues) - Dr Elaine Vickers
11:45 Clinical Sessions (Day 2) close
12:00 Closing Keynote Speaker
Professor Thomas Helleday
The concept of targeting DNA repair for cancer treatment will be described, and description of how mutations in DNA repair pathways can guide responding patient populations. Recent advances in pre-Clinical and Clinical development of evolving DNA repair inhibitors will be covered along with presentation of a new open innovation model for drug development and how this may influence wider treatment of cancer. 
13:00 Lunch & Exhibition
13:30 - 14:30 WORKSHOP - De-mystifying the science behind cancer immunotherapy  (optional complimentary workshop for HCP's) -
Dr Elaine Vickers
13:30  (onwards) Departures

OPENING KEYNOTE SPEAKER

DR SERGIO A QUEZADA PH.D.
Group Leader, Immune Regulation and Tumour Immunotherapy Lab
CRUK Senior Cancer Research Fellow, UCL Cancer Institute
‘Mobilising Immunity to Fight Cancer’ 

QUESTION TIME

MR PETER SISSONS
Chair of Question Time Broadcaster and Author

DR HELEN BULBECK
Director of services and policy, Brainstrust - the brain cancer people

MR ANDY COWPER
Editor of Health Service Journal

MS HEATHER MONTEVERDE
Macmillan General Manager, Northern Ireland

DR CLIVE PEEDELL 
Consultant Clinical Oncologist
James Cook University Hospital, Middlesbrough

DR NICK VAN AS

Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology


CLINICAL STREAMS – DAY 1 & DAY 2

Thursday 15th June 2017 – 14:30hrs ~ 17:30hrs
Friday 16th June 2017 – 08:45hrs ~ 11:45hrs

BREAST

CHAIR – DR ALISON JONES
Consultant Medical Oncologist, University College London Hospital
New Advances in Breast Cancer; who when and what?

'Rapid advances in the recognition of molecular subtypes in breast cancer have allowed the development of new targeted drugs and have raised expectations in patients who feel the era of personalised medicine is with us. But how much do we really know about how to use this scientific knowledge in treatment; who should be tested and when should they be tested? Who should have which drug and can we afford them? This session examines the importance of well-designed clinical trials and the challenges posed by new treatments and how we may address them and indeed afford them including the area of biosimilars which may offset costs. The vexed issue of the timing of sentinel node biopsy in neoadjuvant treatment provokes and interesting (and possibly tribal debate). Finally, with increasing knowledge and treatment possibilities comes increasingly complex communication with patients under stress and how as clinicians do we recognise not only what our treatments should be but what we should be offering patients in terms of emotional and psychological support?'


PROFESSOR CARLO PALMIERI
Professor of Translational Oncology & Medical Oncologist Molecular and
Clinical Cancer Medicine, Clatterbridge, Liverpool
‘Breast Cancer highlights from ASCO.’

PROFESSOR AMANDA J RAMIREZ
Consultant Psychiatrist
Emeritus Professor of Liaison Psychiatry & Psycho-Oncology, King’s College London
Clinical Lead for Psychological Support Services, Leaders in Oncology Care
‘Alongside the best treatments, what do people with cancer need?‘

DR ALISTAIR RING  (DAY 1 ONLY)
Consultant in Medical Oncology,
The Royal Marsden NHS Foundation Trust
‘The challenges of clinical trials for molecular subtypes of breast cancer.’

DR CHARLOTTE FRIBBENS (DAY 2 ONLY)
Le Cure Clinical Research Fellow at the Institute of Cancer Research in London
‘The challenges of clinical trials for molecular subtypes of breast cancer.’

DR ANDREW WARDLEY
Clinical Director of The Christie NIHR/CRUK Clinical Research Facility
‘What should we have? What can’t we have? And how do we decide?’

MR STEVE WILLIAMSON

Consultant Cancer Pharmacist, Head of Chemotherapy, Chair of BOPA
‘Practical implications of the commissioning of biosimilar trastuzumab for clinicians.’
‘BOPA Biosimilar Mission Statement.’

PROFESSOR DAVID DODWELL
Consultant in Clinical Oncology at The Institute of Oncology, St James Hospital , Leeds
'Neoadjuvant therapy - sentinel lymph node biopsy before or after chemotherapy.'
(The case for before)

Vs

DR JULIE DOUGHTY
Senior Lecturer & Consultant Breast Surgeon, Western Infirmary, Glasgow
(The case for after)

CANCER DRUG TOXICITY – SHORT AND LONG-TERM


CHAIR - PROFESSOR RUTH PLUMMER

Clinical Professor of Experimental Cancer Medicine, Northern Institute for Cancer Research, Newcastle University
'This is a new session for the UK Oncology Forum. We will have a team of experts discussing some of the challenges of the acute and chronic toxicities with cancer drugs, both old and new, and how these may best be managed.' 

PROFESSOR JEFF EVANS
Director of Institute/Professor of Translational Cancer Research, University of Glasgow, Beatson Institute
'Immunotherapy of Upper GI Cancers: Opportunities and Challenges.'

DR NIC GOODGER
Consultant Oral & Maxillofacial Surgeon, Kent and Canterbury Hospital
'MRONJ - just another acronym or a pain in the jaw?’

DR CHRIS PLUMMER

Consultant Cardiologist, Freeman Hospital, Newcastle
'The toxic cardiovascular effects of cancer and its treatment.'

MS GAIL PROUT
CNS Skin Cancer, Mount Vernon Hospital
'Cutaneous Complications of Melanoma Medications'

DELIVERING CARE TO THE UK NHS CANCER PATIENT


CHAIR – MS HEATHER MONTEVERDE

Macmillan General Manager, Northern Ireland
CANCER NURSING – HOW LESSONS FROM THE PAST CAN INFLUENCE THE FUTURE
‘There are many factors influencing how we deliver cancer nursing now, how we have worked in the past, and how we plan for the years to come. We’re all aware of the pressures that increasing demand and rising expectations bring to bear on cancer nursing, and the resulting impact on delivery. In this session, we will explore how we can meet the challenges and opportunities of the 21st century, looking at three areas in particular – an ageing population with a focus on the impact of comorbidities and dementia; equality of care for cancer patients within the LGBT community; and the potential of continuing improvements within healthcare technology. We will have an opportunity for lively discussion and debate on how our learning to date within the cancer nursing sector can sharpen our future focus.’


MS LORRAINE BURGESS
Macmillan Dementia Nurse Consultant at the Christie NHS Foundation Trust, Manchester
'The increasing challenge of cancer and dementia as co-morbidities.'

DR SHELLEY DOLAN
Executive Director of Nursing and Midwifery
King’s College Hospital NHS Foundation Trust
'Reflections and lessons learnt over a career in Cancer Nursing.'

PROFESSOR EILÍS MCCAUGHAN
Professor in Cancer Care, Institute of Nursing and Health Research, Ulster University
‘Having the talk, Sexual care and cancer’

DR CHERITH SEMPLE
Macmillan Head and Neck CNS / Ulster University Honorary Fellow
South Eastern Health and Social Care Trust
'Embracing technology to enhance clinical care.'

LOWER GI CANCER SESSION

CHAIR - PROFESSOR RICHARD WILSON
Clinical Professor, School of Medicine, Dentistry and Biomedical Sciences, Queen University Belfast

‘CLINICAL ADVANCES IN COLORECTAL CANCER: SCIENCE IMPACTING PATIENT CARE.’

‘Our improved understanding of colorectal cancer biology coming from basic, translational and clinical research is rapidly impacting on how we best prevent this disease, detect it early, treat our patients and support them in their journey. This session includes updates on 2 mutation-driven forms of CRC. We will hear how to best understand and manage BRAF mutant CRC having learnt that the context of CRC is hugely different from melanoma and other BRAF-driven cancers; and how mutations in DNA mismatch repair and polymerase enzymes can lead to early detection, prevention and new therapeutic strategies for a sub-group of patients predisposed to and diagnosed with CRC. It also covers new data on how best to screen for CRC and how to use FIT both for enhanced screening but also in other aspects of CRC. We will also hear updates from ASCO 2017, where potentially practice-changing results from UK trials were presented. Finally, it explores an area of critical importance that is new to most of us – that of the multi-faceted roles of the gut microbiome and how we can apply our knowledge of this in prevention, diagnosis and treatment of CRC.


DR DAVID CHURCH
Academy of Medical Sciences Clinician Scientist Fellow and Honorary Consultant Medical Oncologist,
Oxford Centre for Cancer Gene Research, University of Oxford
‘Lynch syndrome and DNA POLE mutations in colorectal cancer.’

DR VICKY COYLE
Senior Lecturer and Honorary Consultant in Medical Oncology, Centre for Cancer Research and Cell Biology, Queen’s University Belfast
‘Colorectal cancer highlights from ASCO.’

PROFESSOR GARY MIDDLETON MB, BS, MD, FRCP
Professor of Medical Oncology, Institute of Immunology and Immunotherapy, University of Birmingham
‘Update on BRAF mutant colorectal cancer.

PROFESSOR PAUL O'TOOLE
Professor of Microbial Genomics, School of Microbiology & APC Microbiome Institute, University College Cork
‘The gut microbiome and colorectal cancer.’

PROFESSOR ROBERT J C STEELE
Professor of Surgery, Division of Cancer Research, University of Dundee
‘Bowel cancer screening update and use of Faecal Immunochemical Testing (FIT).’

LUNG

CHAIR - DR MARIANNE NICOLSON
Consultant Medical Oncologist and Honorary Senior Lecturer to NHS Grampian
SMART progress in Lung Cancer: Screening, iMmunotherapy And Radio Therapy updates
'In lung cancer, the rapid rate of progress in treatment development means that guidelines require annual updates. Radiotherapy techniques have improved to allow precision treatment of early tumours, locally advanced cancers and oligometastatic disease. As a single therapeutic entity or in combination with systemic treatments, radiotherapy and research around it is of prime importance in lung cancer. Immunotherapy continues to surprise all specialists in lung cancer treatment since we did not anticipate the huge impact of this treatment approach in these tumours. However, improving outcomes is dominated by the need to prevent or diagnose lung cancer early to maximise cure. In addition to reviewing the evidence from screening trials, the sociopolitical aspects of screening for lung cancer must be a priority discussion. We anticipate a lively session at this year's Oncology Forum!'


PROFESSOR PAUL BAAS
Professor of Thoracic Oncology at the Faculty of Medicine of the University of Amsterdam
‘Immunotherapy in Lung Cancer: facts and frustrations.’

PROFESSOR DAVID BALDWIN
Honorary Professor, Faculty of Medicine & Health Sciences, Nottingham City Hospital
‘CT screening for lung cancer – delay in implementation = lives lost.’

PROFESSOR CORINNE FAIVRE FINN (DAY ONE)
Professor of Thoracic Radiation Oncology at the UoM and
Honorary Consultant Clinical Oncologist The Christie NHS Foundation Trust
‘Controversies in the management of lung cancer with RT in 2017.’

DR FIONA MCDONALD (DAY TWO)
Consultant Clinical Oncologist MA MBBS MRCP FRCR MD, Thoracic malignancies Royal Marsden
‘Controversies in the management of lung cancer with RT in 2017.’

MELANOMA

CHAIR - DR PAUL NATHAN
Consultant Medical Oncologist, Mount Vernon Hospital
'Everything You Need to Know About Melanoma'
'This interactive case-based session focuses on key areas that may change the way you currently look after your melanoma patients and their families. We will discuss the identification and management of patients and families at high risk of developing melanoma, changes in surgical management of loco-regional disease, and which patients should be treated with which new drugs and when. The session will be an opportunity to discuss and debate with all who attend and an experienced expert panel.'


DR VERONIQUE BATAILLE
Consultant Dermatologist, Hemel Hempstead Hospital
‘Identification of patients and families at high risk of melanoma.’ - case based discussion

MR HOWARD PEACH
Consultant Plastic & Reconstructive Surgeon, Leeds Teaching Hospitals
'The changing role of surgery for stage III and loco-regional disease.'

DR HEATHER M SHAW
Consultant in Medical Oncology, Melanoma and Early Phase Trials
University College London Hospital and Mount Vernon Cancer Centre
'ASCO Melanoma Hotspots & Systemic treatments in Melanoma.'

PROSTATE

DR NICK VAN AS
'Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology
Prostate cancer treatments have developed significantly in the last ten years. The greater depth of understanding of the natural history of the disease has allowed for the increased use of active surveillance and improvements in radical surgery and radiation based techniques leading to less toxicity in treatment of localised disease. There have also been significant advances in castrate resistant disease with dramatic improvements in survival due to development of new systemic therapies. One of the areas of significant challenge remains locally advanced high grade and oligo-metastatic disease. We know that although we can improve outcome in locally advanced disease there remains a significant risk of progression and death from this disease state. With the recent CHARTED and STAMPEDE data showing significant improvements in survival with the use of chemotherapy in hormone sensitive metastatic disease, and a clear progression free survival advantage in locally advanced disease, we pose the provocative question can you cure the previously incurable and how do we design treatments and trials to improve outcome in this setting. We have an excellent panel of experts to discuss and explore these issues.'


PROFESSOR FREDDIE HAMDY
Head of the Nuffield Department of Surgical Sciences
Professor of Urology, and Honorary Consultant Urological Surgeon

DR MARK LINCH MRCP PhD
Consultant Medical Oncologist & Honorary Senior Lecturer, UCL Cancer Institute
‘Systemic therapy for oligometastatic prostate cancer; treating more than what you can see on a scan.’

PROFESSOR GERT DE MEERLEER
Department of Radiation oncology and experimental cancer research, Ghent University, Belgium
'Oligometastatic prostate cancer.'

PROFESSOR JOE O'SULLIVAN
Clinical Director of the Northern Ireland Cancer Centre, Belfast
Professor of Radiation Oncology at the Centre for Cancer Research and Cell Biology, Queen's University Belfast
'Can we cure the previously incurable?" (Molecular Oncology).'

RADIOTHERAPY

CHAIR - PROFESSOR DAVID SEBAG-MONTEFIORE
Professor of Clinical Oncology University of Leeds
Novel agent radiotherapy combinations - the next big step for radiotherapy?

‘In the radiotherapy world there is real excitement about the improvements in radiotherapy treatment. Optimised treatment with SABR, MRI guided radiotherapy and protons all offer the opportunity to improve patient outcomes. Novel agents including immunotherapy provides a very exciting opportunity for further benefit when combined with optimized radiotherapy. This session will highlight the scientific background, the opportunities and experience with this combined approach.’


PROFESSOR ANTHONY CHALMERS
Professor of Clinical Oncology, University of Glasgow
'Combining molecular targeted agents with radiotherapy: rationale, challenges and solutions.'

DR MARTIN FORSTER
University College London Hospital NHS Foundation Trust
'Perspective, insights and experience of novel agent toxicities and early phase studies.'

DR GERRY HANNA
Senior Lecturer and Consultant in Clinical Oncology, Queen’s University Belfast
'Novel agents in combination with Curative Intent Radiotherapy in Stage III NSCLC: why, how, what, when and whom?'

DR ALISON TREE
Consultant Clinical Oncologist, Royal Marsden Hospital/Institute of Cancer Research
'Turbo charging the immune system: The synergy of immunotherapy and radiotherapy.'

UPPER GI CANCER SESSION

CHAIR - DR MARTIN EATOCK
Consultant/Honorary Senior Lecturer in Medical Oncology, Medical Director, Northern Ireland Cancer Network
Pancreatic Cancer in 2017 – The bad and the ugly but is there any good?

‘The outlook for patients with pancreatic cancer is dismal and hasn’t improved in the last 40 years. There have been a number of developments in the management of pancreatic cancer over the last few years with more effective chemotherapeutic regimens, the growing use of neo-adjuvant approaches to treatment in surgical patients, development of surgical techniques allowing a potentially greater number of resections to be performed, however there remains uncertainty about the impact these will have on the overall outcomes for patients with this disease. This session will explore these developments, from early detection through to the treatment of advanced disease and highlight potential developments for the future.’


DR JANET GRAHAM

Honorary Clinical Senior Lecturer, Beatson West of Scotland Cancer centre
'Management of advanced pancreatic cancer – Precision and beyond.'

DR DEREK GROSE

Honorary Clinical Senior Lecturer (Institute of Cancer Sciences) Glasgow
'Is the UK ready to adopt neoadjuvant treatment for patients with resectable pancreatic cancer?'

MR CHRISTIAN MACUTKIEWICZ
Consultant Pancreatico-Biliary & Laparoscopic Surgeon at Leeds Teaching Hospitals NHS Trust
'Surgical Controversies in the management of pancreatic cancer.' 

PROFESSOR STEVE PEREIRA

Professor of Hepatology & Gastroenterology
UCL Institute for Liver and Digestive Health, UCL Medical School - Royal Free Hospital Campus
’Shutting the door but has the horse bolted? The possibilities for earlier diagnosis.’ 

DAY 2 – FRIDAY 16TH JUNE 2017

CLOSING KEYNOTE SPEAKER

PROFESSOR THOMAS HELLEDAY
Translational Medicine and Chemical Biology
Karolinska Institutet, SciLifeLab
'Targeting DNA repair in cancer treatments: towards affordable medicine?'
'The concept of targeting DNA repair for cancer treatment will be described and a description of how mutations in DNA repair pathways can guide responding patient populations. Recent advances in pre- Clinical and Clinical development of evolving DNA repair inhibitors will be covered along with presentation of a new open innovation model for drug development and how this may influence wider treatment of cancer.'

OPTIONAL WORKSHOPS

  • WORKSHOP 1 (Industry only) - 10:00hrs ~ 11:00hrs - Dr Elaine Vickers
  • De-mystifying the science behind cancer immunotherapy
  • • Cancer and the immune system – how cancer cells thrive in a leukocyte-rich microenvironment
  • • Immunotherapy – what it’s all about?
  • • Antibody-based therapies that target cancer cell surface proteins
  • • Introduction to T cells and checkpoint proteins
  • • Checkpoint inhibitors targeting CTLA-4, PD-1 and PD-L1
  • • CAR T cell therapy and infiltrating T lymphtocytes (TILs)
  • • Cancer treatment vaccines and oncolytic viruses
  • WORKSHOP 2 (HCPs) - 13:30hrs ~ 14:30hrs - Dr Elaine Vickers
  • De-mystifying the science behind cancer immunotherapy
  • • Cancer and the immune system – how cancer cells thrive in a leukocyte-rich microenvironment
  • • Immunotherapy – what it’s all about?
  • • Antibody-based therapies that target cancer cell surface proteins
  • • Introduction to T cells and checkpoint proteins
  • • Checkpoint inhibitors targeting CTLA-4, PD-1 and PD-L1
  • • CAR T cell therapy and infiltrating T lymphtocytes (TILs)
  • • Cancer treatment vaccines and oncolytic viruses